Aventis Drug Candidate Assessment Finds Half Fail Due To Safety Concerns
Executive Summary
Almost half of Aventis' new drug candidates fail during development because of safety or toxicity concerns, the drug manufacturer's internal data from 2003 show
You may also be interested in...
Bristol Improves R&D Benchmark: 80% Of Pre-Clinical Candidates Enter Trials
Bristol-Myers Squibb has improved its early development success rate to the level that 80% of recommended development candidates make it into human testing, the company said during its R&D update Nov. 17
Bristol Improves R&D Benchmark: 80% Of Pre-Clinical Candidates Enter Trials
Bristol-Myers Squibb has improved its early development success rate to the level that 80% of recommended development candidates make it into human testing, the company said during its R&D update Nov. 17
FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs
FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said